scholarly journals Total testosterone in young men is more closely associated than free testosterone with prostate cancer disparities

2011 ◽  
Vol 3 (3) ◽  
pp. 99-106 ◽  
Author(s):  
Louis Calistro Alvarado
Keyword(s):  
Prostate Cancer ◽  
Young Men ◽  
Free Testosterone ◽  
Cancer Disparities ◽  
Total Testosterone

scholarly journals Acute hormonal response to sublingual androstenediol intake in young men

2002 ◽  
Vol 92 (1) ◽  
pp. 142-146 ◽  
Author(s):  
Gregory A. Brown ◽  
Emily R. Martini ◽  
B. Scott Roberts ◽  
Matthew D. Vukovich ◽  
Douglas S. King
Keyword(s):  
Peak Concentration ◽  
Young Men ◽  
Serum Testosterone ◽  
Free Testosterone ◽  
Total Testosterone ◽  
Serum Estradiol ◽  
Hormonal Response ◽  
Double Blind ◽  
First Pass ◽  
Serum Hormone

The effectiveness of orally ingested androstenediol in raising serum testosterone concentrations may be limited because of hepatic breakdown of the ingested androgens. Because androstenediol administered sublingually with cyclodextrin bypasses first-pass hepatic catabolism, we evaluated the acute hormonal response to sublingual cyclodextrin androstenediol supplement in young men. Eight men (22.9 ± 1.2 yr) experienced in strength training consumed either 20 mg androstenediol in a sublingual cyclodextrin tablet (Sl Diol) or placebo (Pl) separated by at least 1 wk in a randomized, double-blind, crossover manner. Blood samples were collected before supplementation and at 30-min intervals for 3 h after supplementation. Serum hormone concentrations did not change with Pl. Serum androstenedione concentrations were increased ( P < 0.05) above baseline (11.2 ± 1.1 nmol/l) with Sl Diol from 60 to 180 min after intake and reached a peak concentration of 25.2 ± 2.9 nmol/l at 120 min. Serum free testosterone concentrations were increased from 86.2 ± 9.1 pmol/l with Sl Diol from 30 to 180 min and reached a peak concentration of 175.4 ± 12.2 pmol/l at 60 min. Serum total testosterone concentrations increased above basal (25.6 ± 2.3 nmol/l) from 30 to 180 min with Sl Diol and reached a peak concentration of 47.9 + 2.9 nmol/l at 60 min. Serum estradiol concentrations were elevated ( P < 0.05) above baseline (0.08 ± 0.01 nmol/l) from 30 to 180 min with Sl Diol and reached 0.14 ± 0.02 nmol/l at 180 min. These data indicate that sublingual cyclodextrin androstenediol intake increases serum androstenedione, free testosterone, total testosterone, and estradiol concentrations.

scholarly journals Free testosterone and malignant melanoma risk in men: prospective analyses of testosterone and SHBG with 19 cancers in men and postmenopausal women UK Biobank

2020 ◽  
Author(s):  
Eleanor L. Watts ◽  
Aurora Perez-Cornago ◽  
Anika Knuppel ◽  
Konstantinos K. Tsilidis ◽  
Timothy J. Key ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Malignant Melanoma ◽  
Liver Cancer ◽  
Postmenopausal Women ◽  
Multiple Testing ◽  
Cox Regression ◽  
Free Testosterone ◽  
Sex Hormone Binding Globulin ◽  
Total Testosterone ◽  
Uk Biobank

AbstractWe investigated the associations of estimated free and total circulating testosterone and sex hormone-binding globulin (SHBG) with cancer risk in men and postmenopausal women, using a pan-cancer approach, including 19 cancers in UK Biobank.Risk was estimated using multivariable-adjusted Cox regression in up to 182,608 men and 122,112 postmenopausal women who were cancer-free at baseline. Participants diagnosed with cancer within two years of baseline were excluded. Hazard ratios (HRs) and confidence intervals (CIs) were corrected for regression dilution bias using repeat measurements. We accounted for multiple testing using the false discovery rate.In men, higher free testosterone was associated with higher risks of melanoma and prostate cancer (HR per 50 pmol/L increase=1.35, 95% CI 1.14-1.61 and 1.10,1.04-1.18, respectively). Higher total testosterone was associated with an elevated risk of liver cancer (HR per 5 nmol/L=2.45,1.56-3.84), and higher SHBG was associated with a higher risk of liver cancer (HR per 10 nmol/L=1.56,1.31-1.87) and a lower risk of prostate cancer (0.93,0.91-0.96); associations with liver cancer were attenuated after excluding early follow-up. In postmenopausal women, higher free and total testosterone and lower SHBG were associated with elevated risks of endometrial (HR per 10 pmol/L=1.59,1.32-1.90; HR per 0.5 nmol/L=1.34,1.18-1.52 and HR per 25 nmol/L=0.78,0.67-0.91, respectively) and breast cancer (1.32,1.22-1.43;1.24,1.17-1.31 and 0.88,0.83-0.94, respectively).We report a novel association of free testosterone with malignant melanoma in men; our findings also support known associations between sex hormones and risks for prostate, breast and endometrial cancers. The association with liver cancer in men may be attributable to reverse causation.

Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by TMPRSS2:ERG status.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 93-93
Author(s):  
Rebecca E Graff ◽  
Allison Meisner ◽  
Thomas Ahearn ◽  
Michelangelo Fiorentino ◽  
Howard D. Sesso ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Experimental Studies ◽  
Free Testosterone ◽  
Sex Hormone ◽  
Health Study ◽  
Total Testosterone ◽  
Prostate Cell ◽  
Hormone Levels ◽  
Increased Risk ◽  
Nested Case Control

93 Background: Experimental studies have shown that androgen receptor stimulation can facilitate formation of the TMPRSS2:ERG gene fusion in prostate cell lines. No study has tested whether higher pre-diagnostic circulating sex hormone levels in men increase the risk of developing TMPRSS2:ERG positive prostate cancer specifically. Methods: We conducted a nested case-control study of 200 prostate cancer cases and 1,057 controls from the Physicians’ Health Study and Health Professionals Follow-up Study. We examined associations between pre-diagnostic circulating levels of total testosterone, free testosterone, DHT, androstanediol glucuronide, estradiol, and SHBG and risk of prostate cancer by TMPRSS2:ERG status. TMPRSS2:ERG was assessed by ERG immunohistochemistry. We used multivariable unconditional polytomous logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for risk of fusion-positive (n = 94) and, separately, fusion-negative (n = 106) disease. Results: Free testosterone was significantly associated with the risk of ERG-positive prostate cancer (OR: 1.37, 95% CI: 1.05-1.77), but not ERG-negative prostate cancer (OR: 1.09, 95% CI: 0.86-1.38) (p-diff: 0.17). None of the remaining hormones evaluated showed clear differential associations with ERG-positive versus ERG-negative disease. Conclusions: These findings provide some suggestive evidence that higher pre-diagnostic free testosterone levels are associated with an increased risk of developing TMPRSS2:ERG positive prostate cancer but are not associated with prostate cancer that lacks TMPRSS2:ERG.

The predictive power of free (vs. total) testosterone in aggressive prostate cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16570-e16570
Author(s):  
Maxwell M Towe ◽  
Linda My Huynh ◽  
Farouk El Khatib ◽  
Mohamad M Osman ◽  
Faysal A Yafi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Free Testosterone ◽  
Protective Role ◽  
Current Data ◽  
Total Testosterone ◽  
Gleason Grade ◽  
Grade Group ◽  
Stage Disease ◽  
Prostate Cancers

e16570 Background: The role of testosterone in prostate growth and the development of prostate cancer is a controversial topic. Most current data suggest that lower testosterone leads to higher grade conversion, whereas higher testosterone may serve a protective role in preventing both development and recurrence. We seek to analyze whether free testosterone (FT) values can predict aggressiveness in prostate cancers. Methods: We retrospectively reviewed 830 patients who presented to a single surgeon for evaluation and management of prostate cancer. Total Testosterone (TT) and FT values were obtained on each patient at initial visit. All patients underwent radical prostatectomy and samples from surgery were sent for grading and staging. Patients were stratified by FT quartile (25th [≤ 4.42 ng/dL], 50th [4.43 – 5.60 ng/dL], 75th [5.61 – 6.95 ng/dL], and 100th [≥ 6.96 ng/dL]). Results: Of 830 patients, 168 (22.2%), 330 (39.8%), 188 (22.7%), 46 (5.5%), and 98 (11.8%) had GS 3+3, 3+4, 4+3, 4+4, and ≥4+5, respectively. Mean FT values for each Gleason grade group (GGG) were significantly different (p = 0.008). Mean FT was also lower in patients with higher stage disease (p = 0.01). In contrast, TT did not differ significantly among GGG (p = 0.489) or stage (p = 0.670). Patients who had a FT level in the lowest quartile (≤ 4.42 ng/dL) had a higher proportion of GGG 5 (15.6%) than patients in the highest quartile (≥ 6.96 ng/dL) (6.2%) (p = 0.002). After adjusting for age, prostate specific antigen (PSA), and body mass index (BMI) in multivariate analysis, lower FT was a significant predictor of high-risk score 9-10 (OR: 0.912, 95% CI: 0.836-0.994, p = 0.036). These trends showed strong correlation in pathologic stage (p = 0.057), but larger numbers are needed to gauge effect size. Conclusions: Based on our data, biochemically low FT may be a risk factor for high grade and high stage cancer. These results have implications for the current recommendations for testosterone therapy, which is contraindicated in men with prostate cancer. [Table: see text]

Behavior of free Testosterone in Patients with Prostate Cancer on Androgen Deprivation Therapy

2005 ◽  
Vol 20 (2) ◽  
pp. 119-122 ◽  
Author(s):  
J. Morote ◽  
S. Esquena ◽  
J.M. Abascal ◽  
E. Trilla ◽  
L. Cecchini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Free Testosterone ◽  
Serum Levels ◽  
Cross Sectional Study ◽  
Androgen Deprivation ◽  
Control Group ◽  
Total Testosterone ◽  
Cross Sectional

Objectives Determination of free testosterone (FT) serum level is an efficient method to evaluate bioavailable testosterone. We analyzed the behavior of serum FT in patients with prostate cancer receiving androgen deprivation therapy (ADT) and correlated FT with total testosterone (TT). We also analyzed the efficiency of both isoforms in the evaluation of the ADT. Methods Serum levels of TT and FT were determined in 191 patients with prostate cancer in a cross-sectional study. A subset of 56 patients submitted only to radical prostatectomy served as control group. The remaining 135 patients with advanced prostate cancer on three-month LHRH agonist treatment comprised the study group. The median age of the population was 73 years (range, 53–86 years) and the median time on ADT was 42 months (6–198). Results A significant correlation and linear regression between TT and FT was observed (r2 0.948). The efficiency of TT and FT to discriminate patients with and without ADT was similar (AUC: 0.993 and 0.995, respectively, p>0.05). A castration level of serum FT established at 1.7 pg/mL had a sensitivity of 85.9% and a specificity of 100%, which are similar to the sensitivity and specificity of 50 ng/dL of TT. All patients without ADT had levels of serum TT and FT above the castration level. In 19 of the 135 (14.1%) patients on ADT serum TT was above 50 ng/dL. In 12 of these 19 patients (63.2%) serum FT was below 1.7 pg/mL while in seven patients (5.2%) FT was also above the castration level. Conclusions The castration level of FT was established at 1.7 pg/mL. Serum TT and TF correlated very well; however, they seemed to provide complementary information in the evaluation of ADT efficiency. 14.1% of the patients on ADT failed to reach the castration level of serum TT; determination of serum FT in these patients would reduce this rate to 5.2%.

Free testosterone correlated with erectile dysfunction severity among young men with normal total testosterone

2018 ◽  
Vol 31 (2) ◽  
pp. 132-138 ◽  
Author(s):  
Yan-Ping Huang ◽  
Wei Liu ◽  
Sheng-Fu Chen ◽  
Yi-Dong Liu ◽  
Bin Chen ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Young Men ◽  
Free Testosterone ◽  
Total Testosterone

Dihydrotestosterone is elevated following sprint exercise in healthy young men

2013 ◽  
Vol 114 (10) ◽  
pp. 1435-1440 ◽  
Author(s):  
Alan A. Smith ◽  
Rebecca Toone ◽  
Oliver Peacock ◽  
Scott Drawer ◽  
Keith A. Stokes ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Venous Blood ◽  
Young Men ◽  
Free Testosterone ◽  
Total Testosterone ◽  
Cycle Exercise ◽  
Skeletal Muscle Function ◽  
Sprint Exercise ◽  
Rate Maximum ◽  
Repeat Sprint

Dihydrotestosterone (DHT) exerts both functional and signaling effects extending beyond the effects of testosterone in rodent skeletal muscle. As a primer for investigating the role of DHT in human skeletal muscle function, this study aimed to determine whether circulating DHT is acutely elevated in men following a bout of repeat sprint exercise and to establish the importance of training status and sprint performance to this response. Fourteen healthy active young men (V̇o2max61.0 ± 8.1 ml·kg body mass−1·min−1) performed a bout of repeat sprint cycle exercise at a target workload based on an incremental work-rate maximum (10 × 30 s at 150% Wmaxwith 90-s recovery). Venous blood samples were collected preexercise and 5 and 60 min after exercise. Five minutes after exercise, there were significant elevations in total testosterone (TT; P < 0.001), free testosterone (FT; P < 0.001), and DHT ( P = 0.004), which returned to baseline after 1 h. Changes in DHT with exercise (5 min postexercise − preexercise) correlated significantly with changes in TT ( r = 0.870; P < 0.001) and FT ( r = 0.914; P < 0.001). Sprinting cadence correlated with changes in FT ( r = 0.697; P = 0.006), DHT ( r = 0.625; P = 0.017), and TT ( r = 0.603; P = 0.022), and habitual training volume correlated with the change in TT ( r = 0.569, P = 0.034). In conclusion, our data demonstrate that DHT is acutely elevated following sprint cycle exercise and that this response is influenced by cycling cadence. The importance of DHT in the context of exercise training and sports performance remains to be determined.

scholarly journals The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy

2016 ◽  
Vol 88 (1) ◽  
pp. 17 ◽  
Author(s):  
Antonio B. Porcaro ◽  
Beatrice Caruso ◽  
Alessandro Terrin ◽  
Nicolò De Luyk ◽  
Giovanni Cacciamani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Prostate Specific Antigen ◽  
Statistical Significance ◽  
Specific Antigen ◽  
Free Testosterone ◽  
Total Testosterone ◽  
Preoperative Serum ◽  
Total Prostate Specific Antigen ◽  
Index Ratio

Objectives: To evaluate associations of preoperative total prostate specific antigen (PSA) to free testosterone (FT), the PSA/FT index ratio, with features of pathology prostate cancer (PCA) and to investigate its prognostic potential in clustering the PCA population. Patients and methods: After excluding criteria, the records of 220 patients who underwent radical prostatectomy (RP) were retrospectively reviewed. Serum samples of PSA, total testosterone (TT) and FT were collected at 8.00 A.M., one month after biopsies and before RP. The PSA/FT ratio was computed in the population of patients who were clustered in groups according to ranking intervals of the PSA/FT ratio which identified at least 4 clusters which were coded as A, B, C, and D. The independent associations of the PSA/FT index ratio were assessed by statistical methods and a two-sided P &lt; 0.05 was considered to indicate statistical significance. Results: TT correlated to FT which was a significant predictor of PSA in the population of patients who were subsequently clustered, according to increasing interval values of the PSA/FT index ratio, in groups that showed a stronger linear association of FT with PSA. The PSA/FT index ratio significantly associated with pathology features of prostate cancer such as pathology Gleason score (pGS), invasion of the seminal vesicles (pT3b), proportion of positive cores (P+) and proportion of cancer involving the volume of the prostate. In the population of patients, TT, PSA/FT index ratio and P+ independently associated with pGS ≥ 7 and pT3b; moreover, the odds ratio (OR) of the PSA/FT index ratio resulted 9.11 which was stronger than TT (OR = 1.11) and P+ (OR = 8.84). In the PCA population, TT, PSA/FT index ratio and P+ also independently associated with pT3b PCA; interestingly, the OR of PSA/FT index resulted 54.91 which was stronger than TT (OR = 1.31) and P+ (26.43). Conclusions: Preoperative PSA/FT index ratio is an independent strong factor which directly associates with aggressive features of pathology PCA; moreover, it might express prognostic potential for clustering the patient population in risk classes. Confirmatory studies are required.

Sign in / Sign up

Export Citation Format

Share Document